Compare Crispr Therapeutics AG (CRSP) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Sibanye Stillwater Ltd — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Sibanye Stillwater Ltd trades at $8.56 (market cap $6.03B). The key difference: Sibanye Stillwater Ltd is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 3.63% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | SBSW | |
|---|---|---|
Market Cap | $4.97B | $6.03B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $21.12 |
52-Week Low | $44.34 | $7.27 |
Enterprise Value | $3.32B | $7.66B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Sibanye Stillwater (SBSW) trades at $8.42, down 1.52% with bearish technical signals. The company shows mixed fundamentals with a negative net income margin of -3.99% and ROE of -12.38% for 2024, though revenue has stabilized at $112.13B. Recent news highlights a turnaround narrative with EBITDA growth and debt reduction plans. Technical indicators show bearish momentum with support at $8 and resistance at $9.
The stock presents a high-risk opportunity with significant upside to the $14.25 consensus price target. Key risks include persistent negative profitability, high debt levels, and commodity price volatility. Analyst sentiment is cautiously optimistic with 43% buy ratings, but investors should weigh the turnaround potential against ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
